A randomised multicentre single blind comparison of a cannabinoid anti-emetic (Levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy

Hutcheon, A. W.; Palmer, Jamie; Soukop, M.; Cunningham, David; McArdle, C. S.; Welsh, John; Stuart, Fraser; Sangster, Graeme; Kaye, Stanley B.; Charlton, D.E.; Cash, Haydn

doi:10.1016/0277-5379(83)90032-9

Cited by 24 publications

(15 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the only parallel group trial that reported preference as an end point,45 78% of the patients who had received chlorpromazine and 58% of those who had received levonantradol wished to receive the same drug for future chemotherapy cycles. This difference that was not significant (relative risk 0.74, 95% confidence interval 0.50 to 1.09).…”

Section: Resultsmentioning

confidence: 99%

Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic

Tramèr

Carroll²,

Campbell³

et al. 2001

BMJ

516

264

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic

Tramèr

Carroll²,

Campbell³

et al. 2001

BMJ

516

264

View full text Add to dashboard Cite

show abstract

“…Given intramuscularly at standard doses (100 mg total dose), CLP was better than placebo [15] and equally as effective as droperidol (6 mg/m2) [15], MCP (5 mg/kg) [16] or levonantadrol [17] in controlling emesis induced by cytotoxic regimens with and with out cisplatin. A high rate of sedation with no extrapyramidal reactions was also observed.…”

Section: Discussionmentioning

confidence: 99%

Effective Control of Moderate-Dose Cisplatin-induced Emesis by a Short-Course Regimen Including Metoclopramide, Chlorpromazine and Hydrocortisone: Results of a Randomized Trial with Metoclopramide Alone

Pollera¹,

Calabresi²

1989

Oncology

View full text Add to dashboard Cite

To improve the antiemetic effectiveness of a previously selected short regimen of moderate-dose metoclopramide (MCP), 80 patients were randomized to receive MCP either alone (regimen A) or in combination with low-dose chlorpromazine (CLP) and high-dose hydrocortisone (HDC) (regimen B) with the first course of cisplatin (50 mg/m²). The antiemetic effect was assessed over a 24-hour period only by objective means (duration and volume of vomiting in overnight fasting patients). The response was classified as follows: no emesis (absence of vomiting), partial protection (up to 100 ml of vomiting) and antiemetic failure (more than 100 ml). For regimen A, this study confirms the results previously reported over a 6-hour period. Regimen B provided better emetic control, significantly reducing the prevalence (p = 0.03) and severity (p = 0.02) of emesis, as well as the median volume (p <0.006) and duration (p <0.02) of vomiting. Except for the higher incidence of sedation, neither limiting nor unexpected toxicities were observed with the multidrug regimen. The male sex and antiemetic regimen B were the only favorable independent prognostic factors recognized by means of a multivariate analysis using a logistic model. This study therefore shows the usefulness of combining a lower dose of MCP and CLP, together with a high-dose HDC in a short regimen, suitable for outpatients receiving moderate-dose cisplatin. The better emesis control in the highly resistant group of female patients warrants further studies and a more aggressive approach.

show abstract

“…Another THC analogue, levonantradol, has both anti-emetic and powerful analgesic properties. It was effective in the treatment of post surgical pain (Jain et al, 1981), and as an antiemetic in cancer patients (Cronin et al, 1981;Hutcheon et al, 1983;Stambaugh et al, 1984). However, adverse events were common, and sometimes severe and dose limiting (Cronin et al, 1981;Hutcheon et al, 1983), thus the drug was judged unacceptable and the programme was dropped (Dr K. Koe quoted in (Iversen, 2000)).…”

Section: Licensed Formulationsmentioning

confidence: 99%

Cannabinoids and Neuropathic Pain

Brownjohn¹,

Ashton²

2012

Neuropathic Pain

View full text Add to dashboard Cite

A randomised multicentre single blind comparison of a cannabinoid anti-emetic (Levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy

Cited by 24 publications

References 3 publications

Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic

Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic

Effective Control of Moderate-Dose Cisplatin-induced Emesis by a Short-Course Regimen Including Metoclopramide, Chlorpromazine and Hydrocortisone: Results of a Randomized Trial with Metoclopramide Alone

Cannabinoids and Neuropathic Pain

Contact Info

Product

Resources

About